Do you want to read an article? Please log in or register.
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 - Prospective Randomized Placebo-Controlled Double-Blind Trial
Gastrointestinal Cancer
Related content
Gastrointestinal Cancer
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
Lancet Gastroenterol Hepatol
Chia JWK, Segelov E, Deng Y, Ho GF, Wang W, Han S, Sharma A, Ding K, Chen G, Jeffery MG, Tham CK, Ahn JB, Nott L, Zielinski R, Chao TY, van Hagen T, Wei PL, Day F, Mehta S, Yau T, Peng J, Hayes TM, Li Y, Gandhi M, Foo EMJ, Rahman N, Rothwell P, Ali R, Simes J, Toh HC
doi: 10.1016/S2468-1253(24)00387-X
Inflammatory Bowel Disease
Mucosal Healing With Vedolizumab in Patients with Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial
Clin Gastroenterol Hepatol
Jairath V, Feagan BG, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, Bressler B, Ferrante M, Hart A, Lindner D, Escher A, Jones S, Shen B, Travis S
doi: 10.1016/j.cgh.2024.06.037
Gastrointestinal Cancer
Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials
Eur J Cancer
Noronha MM, Costa Almeida LF, Cappellaro AP, Silva LFLD, Conceição LDD, Menezes JSA, Belotto M, Peixoto RD'
doi: 10.1016/j.ejca.2025.115476
Inflammatory Bowel Disease
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
Lancet Gastroenterol Hepatol
D'Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, Roblin X, Peyrin-Biroulet L, West R, Mares WGN, Duijvestein M, Gecse KB, Feagan BG, Zou G, Hulshoff MS, Mookhoek A, Oldenburg L, Clasquin E, Bouhnik Y, Laharie D
doi: 10.1016/S2468-1253(24)00317-0
COMMENTED
Inflammatory Bowel Disease
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Nutrients
Biedermann L, Doulberis M, Schreiner P, Nielsen OH, The FO, Brand S, Burk S, Hruz P, Juillerat P, Krieger-Grübel C, Leu K, Leventhal GE, Misselwitz B, Scharl S, Schoepfer A, Seibold F, Herfarth H, Rogler G
doi: 10.3390/nu16234197
Gastrointestinal Cancer
Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial
J Clin Oncol
Lu J, Xing J, Zang L, Zhang C, Xu L, Zhang G, He Z, Sun Y, Feng Y, Du X, Hu S, Chi P, Huang Y, Wang Z, Zhong M, Wu A, Zhu A, Li F, Xu J, Kang L, Suo J, Deng H, Ye Y, Ding K, Xu T, Zhang Y, Zhang Z, Zheng M, Su X, Xiao Y, RELARC study group
doi: 10.1200/JCO.24.00393
Gastrointestinal Cancer
A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801
Int J Cancer
Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, Yuki S, Sawada K, Ishiguro A, Sogabe S, Ando T, Sasaki Y, Yoshikawa A, Nakamura M, Dazai M, Tateyama M, Muto O, Kotaka M, Sagawa T, Muranaka T, Hatanaka K, Takagi R, Sakata Y
doi: 10.1002/ijc.35116
Gastrointestinal Cancer
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)
J Clin Oncol
Takashima A, Hamaguchi T, Mizusawa J, Nagashima F, Ando M, Ojima H, Denda T, Watanabe J, Shinozaki K, Baba H, Asayama M, Hasegawa S, Masuishi T, Nakata K, Tsukamoto S, Katayama H, Nakamura K, Fukuda H, Kanemitsu Y, Shimada Y, Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG)
doi: 10.1200/JCO.23.02722
Inflammatory Bowel Disease
Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis
Gastroenterology
Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Zou G, Yuan Y, Sands BE, Feagan BG, Dulai PS, Narula N, Ma C, Jairath V
doi: 10.1053/j.gastro.2024.10.009